Research programme: progenitor cell activators - Frequency Therapeutics

Drug Profile

Research programme: progenitor cell activators - Frequency Therapeutics

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Frequency Therapeutics
  • Developer Frequency Therapeutics; Harvard University; US Army Institute of Surgical Research
  • Class Small molecules
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Musculoskeletal disorders
  • Research Noise-induced hearing loss; Type 1 diabetes mellitus

Most Recent Events

  • 22 Feb 2018 Early research in Type-1 diabetes mellitus in USA (unspecified route)
  • 15 Feb 2018 Frequency Therapeutics establishes CRADA with Harvard University and the US Army Institute of Surgical Research for the development of progenitor cell activators in Musculoskeletal disorders
  • 15 Feb 2018 Preclinical trials in Musculoskeletal disorders in USA (unspecified route) before February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top